Lv31
320 积分 2022-06-07 加入
AAN unveils new guidelines for MS disease-modifying therapy
4天前
待确认
[Clinical analysis of 9 children with refractory N-methyl-D-aspartate receptor antibody encephalitis children treated with tocilizumab]
19天前
已完结
Controversies in immunotherapy for anti-NMDA receptor encephalitis: a scoping review with a proposal of operational definitions
19天前
已完结
Clinical practice guidelines for multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease 2023 in Japan
24天前
已完结
Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea
25天前
已关闭
Are monoclonals the only panacea for treatment of aquaporin-4 positive NMOSD? Experience from a low-&middle-income (LMIC) region
25天前
已完结
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
25天前
已完结
Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations
25天前
已完结
Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy
1个月前
已完结
Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder
1个月前
已完结
皖公网安备34019202002308
